What Emboline does

Emboline, Inc. is a privately held, venture-backed medical device company headquartered in Santa Cruz, California, developing the Emboliner® Full-Body Embolic Protection Catheter (EPC-03) for use during transcatheter aortic valve replacement (TAVR) and other structural heart procedures. The device is a transfemorally delivered, dual-layer Nitinol mesh filter with an integrated self-sealing access port, designed to capture embolic debris released into the bloodstream and provide protection to all three cerebral vessels as well as the kidneys and other organs — distinguishing it from cerebral-only protection devices such as Boston Scientific's Sentinel CPS. The company is led by founder/CTO Amir Belson, M.D. (a serial entrepreneur with prior exits to Intuitive Surgical, C.R. Bard, and Stryker) and CEO Scott Russell (a Nitinol technology veteran with prior leadership roles at Cordis/NDC). The leadership team has collectively authored more than 825 issued and pending patents.

Emboline has not yet commercialized its product; the Emboliner is investigational and labeled "not available for sale." In March 2026, the company reported positive results from its U.S. pivotal IDE trial (PROTECT H2H), a 522-patient head-to-head randomized study against Sentinel CPS, meeting all primary and secondary safety and efficacy endpoints with superior debris capture (93 vs. 31 particles ≥150µm), higher technical success (95.9% vs. 87.1%), and non-inferior 30-day MACCE (4.5% vs. 5.0%). The company has raised approximately $93 million across disclosed funding rounds, including a $55M Series D in May 2021 and a $20M growth capital round from Trinity Capital in March 2026.

The business model is hardware sales of a single-use disposable catheter to hospitals and interventional cardiology / structural heart programs performing TAVR. Commercial launch is planned in the United States (pending FDA PMA) and Europe (pending CE Mark) via direct hospital sales, supported by medical conference presence (ACC, TCT, PCR London Valves, euroPCR), peer-reviewed publications, and KOL relationships established through the clinical trial program. The company has 11-50 employees and was founded circa 2011-2014.

Name

Emboline

Legal name

Emboline, Inc.

Website

https://emboline.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Emboline is a private medical device company developing the Emboliner Full-Body Embolic Protection Catheter, a dual-layer Nitinol mesh filter designed to capture embolic debris during TAVR and other structural heart procedures, serving hospitals and interventional cardiology departments.

Ownership category

akta.pro rank

Product category

Embolic Protection Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Embolic protection devices
• Transcatheter heart valve
• TAVR cerebral protection
• Aortic embolic filters
• Interventional cardiology devices

Headquarters

HQ city

Santa Cruz

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Emboline generates revenue through sale of the Emboliner Embolic Protection System, a disposable medical device used during TAVR procedures. The company is pre-commercial, preparing for launch following regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Emboline develops and manufactures the Emboliner® Full-Body Embolic Protection Catheter (EPC-03), a single-use, dual-layer Nitinol mesh filter catheter with an integrated self-sealing access port designed to capture and remove embolic debris released during transcatheter aortic valve replacement (TAVR) and other structural heart procedures. The device is deployed transfemorally into the aorta to provide comprehensive cerebral and systemic protection (brain, kidneys, and other organs) from ischemic complications. The company also offers the EPT-01 Angiographic Pigtail (130cm) as an accessory component.

Product overview

Emboline offers a single unified product: the Emboliner® Full-Body Embolic Protection Catheter (EPC-03), a medical device consisting of a dual-layer Nitinol mesh filter with an integrated expanding access port. The device is deployed through the transfemoral puncture, positioned in the aorta to capture debris liberated during transcatheter aortic valve replacement (TAVR) and other structural heart procedures, protecting the brain, kidneys, and other organs. The product is investigational and not yet commercially available.

Differentiator

Problem solved

Functional benefit

Brands

• Emboliner: Emboliner® Full-Body Embolic Protection System - the company's lead product designed to provide complete cerebral and systemic embolic protection during structural heart interventions such as TAVR.

Products and services

• Emboliner® Embolic Protection Catheter (EPC-03) A single-use, dual-layer cylindrical Nitinol mesh filter catheter with an integrated self-sealing expanding access port. The device is deployed transfemorally into the aorta during TAVR and other structural heart procedures to capture embolic debris (calcified valve tissue, thrombus, foreign material) released into the bloodstream, providing full-body protection covering all three cerebral vessels and the kidneys/other organs. Compatible with leading self-expanding and balloon-expandable TAVR systems.
• EPT-01 Angiographic Pigtail Catheter (130cm) 130cm angiographic pigtail catheter offered by Emboline as an accessory component compatible with the Emboliner Embolic Protection System for structural heart and TAVR procedures in both USA and EU markets.

Quantifiable outcome

• 93 vs 31 particles captured (≥150µm) - superior debris capture vs Sentinel CPS
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• SWAT Medical ABcoreOthers · 4 April 2024Emboline acquired a significant embolic protection intellectual property portfolio from SWAT Medical AB, strengthening its IP position in the embolic protection technology space.

Scale indicators6 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Boston Scientific: Boston Scientific markets the Sentinel CPS, the only commercially established embolic protection device for TAVR and Emboline's direct head-to-head comparator in the PROTECT H2H pivotal trial. Both target the same structural heart / interventional cardiology customers with catheter-based embolic protection during TAVR.
• AorticLab S.r.l. AorticLab is developing the FLOWer embolic protection device for TAVR and structural heart procedures in Europe, directly overlapping Emboline's product positioning. Emboline previously pursued patent infringement claims against AorticLab in the UPC, indicating direct competitive overlap.

Broad incumbents

• Edwards Lifesciences: Edwards is the market leader in transcatheter aortic valve replacement (SAPIEN platform) and a structural heart incumbent whose TAVR procedures drive demand for embolic protection adjuncts like Emboliner. Comparable because Emboline's device is used during Edwards' TAVR cases.
• Medtronic: Medtronic is a leading TAVR provider (CoreValve/Evolut platform) and broad structural heart incumbent. Emboliner is designed to be compatible with leading TAVR systems including Medtronic's, making Medtronic a strategic customer and a broad incumbent in the same procedure ecosystem.
• Abbott: Abbott is a major structural heart player (Navitor, MitraClip, TriClip) and a TAVR competitor, providing a comparable addressable procedural base where embolic protection adjuncts like Emboliner could be deployed across both aortic and mitral transcatheter procedures.
• Inari Medical: Inari Medical specializes in catheter-based thrombectomy and venous/arterial embolic protection devices (FlowTriever, ClotTriever). While focused on venous thromboembolism, it shares the catheter-based embolic protection technology paradigm and interventional endovascular customer base.
• Penumbra: Penumbra develops catheter-based thrombectomy and embolic protection systems (Indigo, Lightning). It is a broader incumbent in interventional catheter-based embolic/debris management, addressing similar clinical problems to Emboline's full-body embolic protection in different vascular territories.

Emerging players

• Protembis GmbH: Protembis is developing the ProtEmbo cerebral embolic protection system for TAVR, an emerging competitor with a similar indication and procedural workflow overlap. It is an early-stage European peer focused on the same embolic protection opportunity during structural heart interventions.
• Contego Medical: Contego Medical develops embolic protection and delivery technologies for endovascular procedures, with overlapping technology foundations (catheter-based filtration) and interventional cardiology/structural heart target customers.
• InspireMD: InspireMD markets carotid and embolic protection devices (CGuard, MeshGuard) for endovascular procedures and is an emerging peer in embolic protection, sharing the same catheter-based mesh/filter technology approach for cerebral and systemic embolic risk mitigation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/emboline-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emboline